IMODIUM A-D EZ CHEWS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IMODIUM A-D EZ CHEWS (IMODIUM A-D EZ CHEWS).
Loperamide is a synthetic piperidine derivative that acts directly on intestinal muscle to slow peristalsis, thereby reducing stool frequency and increasing stool consistency. It binds to μ-opioid receptors in the myenteric plexus of the gastrointestinal tract, decreasing acetylcholine release and inhibiting peristalsis. It has minimal central nervous system activity due to poor bioavailability and efflux by P-glycoprotein.
| Metabolism | Primarily metabolized by CYP2C8 and CYP3A4 in the liver; undergoes glucuronidation. Loperamide and its metabolites are excreted mainly in feces via biliary elimination, with minimal renal excretion. |
| Excretion | Primarily hepatic metabolism with biliary excretion of metabolites; ~1% renal excretion of unchanged drug. Fecal elimination accounts for ~90% of the dose, mainly as conjugated metabolites, with ~1% as unchanged loperamide. |
| Half-life | Terminal elimination half-life is approximately 9–14 hours (mean ~10.8 hours) in healthy adults. In patients with hepatic impairment, half-life may be prolonged. |
| Protein binding | Approximately 97% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 4–5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is about 40–65% due to extensive first-pass hepatic metabolism. For the orally disintegrating tablet, bioavailability is similar to conventional oral formulations. |
| Onset of Action | Orally disintegrating tablet: Approximately 30–60 minutes. |
| Duration of Action | Antidiarrheal effect persists for approximately 4–6 hours after a single dose, though clinical duration may extend up to 8 hours with dose-dependent response. |
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use (prescription: up to 16 mg/day).
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | No dose adjustment required for mild-to-moderate renal impairment. Not studied in severe renal impairment; caution advised. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% due to decreased metabolism; monitor for CNS toxicity. |
| Pediatric use | Children 6-8 years (20-30 kg): 2 mg orally after first loose stool, then 1 mg after each subsequent loose stool; maximum 4 mg/day. Children 9-11 years (30-40 kg): 2 mg initially, then 1 mg after each loose stool; maximum 6 mg/day. Children 12+ years: same as adult. |
| Geriatric use | Use with caution due to potential for electrolyte disturbances and constipation. Start at lower end of dosing range; monitor for CNS effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IMODIUM A-D EZ CHEWS (IMODIUM A-D EZ CHEWS).
| Breastfeeding | Loperamide is excreted into breast milk in low amounts, estimated infant dose <2% of maternal weight-adjusted dose. M/P ratio not determined. Use caution; prolonged high-dose exposure may cause infant constipation or CNS effects. |
| Teratogenic Risk | Loperamide is not teratogenic in animal studies. Human data are limited; first-trimester exposure does not show increased risk of major malformations. Second and third trimester risks are unknown but no fetal harm reported. Avoid high doses and prolonged use. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to loperamide or any component","Children <2 years of age","Acute dysentery characterized by blood in stool and fever","Acute ulcerative colitis","Pseudomembranous colitis","Bacterial enterocolitis caused by invasive organisms (e.g., Salmonella, Shigella, Campylobacter)"]
| Precautions | ["Risk of QT prolongation and cardiac arrhythmias (especially at high doses or with CYP3A4 inhibitors)","May cause severe constipation or paralytic ileus, especially in patients with dysentery or acute ulcerative colitis","Not recommended in children <2 years due to respiratory depression risk","Hepatotoxicity reported with chronic use","Do not use if diarrhea accompanied by fever, bloody stools, or suspected bacterial etiology"] |
Loading safety data…
| Fetal Monitoring |
| No specific monitoring required for loperamide. Monitor maternal diarrhea severity and hydration. In pregnancy, assess fetal growth if used chronically. |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. Diarrhea treatment may improve fertility by correcting underlying conditions. |